ASPHF
Price
$5.83
Change
+$0.40 (+7.38%)
Updated
Jan 22 closing price
Capitalization
1.66B
PYPD
Price
$2.48
Change
+$0.03 (+1.22%)
Updated
Apr 11 closing price
Capitalization
25.27M
23 days until earnings call
Ad is loading...

ASPHF vs PYPD

Header iconASPHF vs PYPD Comparison
Open Charts ASPHF vs PYPDBanner chart's image
ASCENTAGE PHARMA GROUP
Price$5.83
Change+$0.40 (+7.38%)
Volume$400
Capitalization1.66B
PolyPid
Price$2.48
Change+$0.03 (+1.22%)
Volume$1.99K
Capitalization25.27M
ASPHF vs PYPD Comparison Chart
Loading...
PYPD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASPHF vs. PYPD commentary
Apr 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASPHF is a Hold and PYPD is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 14, 2025
Stock price -- (ASPHF: $5.82 vs. PYPD: $2.48)
Brand notoriety: ASPHF and PYPD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASPHF: 100% vs. PYPD: 16%
Market capitalization -- ASPHF: $1.66B vs. PYPD: $25.27M
ASPHF [@Biotechnology] is valued at $1.66B. PYPD’s [@Biotechnology] market capitalization is $25.27M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASPHF’s FA Score shows that 0 FA rating(s) are green whilePYPD’s FA Score has 0 green FA rating(s).

  • ASPHF’s FA Score: 0 green, 5 red.
  • PYPD’s FA Score: 0 green, 5 red.
According to our system of comparison, PYPD is a better buy in the long-term than ASPHF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PYPD’s TA Score shows that 4 TA indicator(s) are bullish.

  • PYPD’s TA Score: 4 bullish, 5 bearish.

Price Growth

ASPHF (@Biotechnology) experienced а 0.00% price change this week, while PYPD (@Biotechnology) price change was -1.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.26%. For the same industry, the average monthly price growth was -16.13%, and the average quarterly price growth was -17.16%.

Reported Earning Dates

PYPD is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+0.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ASPHF($1.66B) has a higher market cap than PYPD($25.3M). ASPHF YTD gains are higher at: 116.543 vs. PYPD (-18.421).
ASPHFPYPDASPHF / PYPD
Capitalization1.66B25.3M6,569%
EBITDAN/A-26.41M-
Gain YTD116.543-18.421-633%
P/E RatioN/AN/A-
RevenueN/A0-
Total CashN/A15.6M-
Total DebtN/A9.62M-
TECHNICAL ANALYSIS
Technical Analysis
PYPD
RSI
ODDS (%)
Bullish Trend 4 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
74%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
PYPD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.401.38
+5.52%
GameStop Corp
AAPL198.157.73
+4.06%
Apple
SPY533.949.36
+1.78%
SPDR® S&P 500® ETF
TSLA252.31-0.09
-0.04%
Tesla
BTC.X83684.980000-1602.132800
-1.88%
Bitcoin cryptocurrency

ASPHF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASPHF has been loosely correlated with NERV. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ASPHF jumps, then NERV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASPHF
1D Price
Change %
ASPHF100%
N/A
NERV - ASPHF
44%
Loosely correlated
+7.41%
CARA - ASPHF
35%
Loosely correlated
N/A
GPCR - ASPHF
31%
Poorly correlated
+5.65%
NURPF - ASPHF
30%
Poorly correlated
N/A
CKPT - ASPHF
29%
Poorly correlated
+0.50%
More

PYPD and

Correlation & Price change

A.I.dvisor tells us that PYPD and MESO have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PYPD and MESO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PYPD
1D Price
Change %
PYPD100%
+1.22%
MESO - PYPD
31%
Poorly correlated
-2.50%
ELEV - PYPD
30%
Poorly correlated
+3.70%
RAPT - PYPD
26%
Poorly correlated
+1.59%
SLGL - PYPD
26%
Poorly correlated
+4.88%
CSBR - PYPD
25%
Poorly correlated
-9.16%
More